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Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare (< 1%) primary liver cancer which contains elements 
of hepatocellular cancer (HCC) and bile duct cancer (CC). On account of the difficulties in reaching preoperative dia-
gnosis, it is frequently diagnosed only after resection is performed. A surgical resection of the liver is the treatment 
of choice, whilst a liver transplant is a rarely implemented option. The prognosis of cHCC-CC tumours is better than 
in CC but worse than in HCC. This paper presents the case report of a 62-year-old man undergoing a left hemihepa-
tectomy for a cHCC-CC liver tumour. 
NOWOTWORY J Oncol 2018; 68, 2: 92–94
Key words: HCC-CC, liver, hemihepatectomy
Introduction 
The simultaneous occurrence of hepatocellular cancer 
(HCC) and bile duct cancer (CC) within a liver tumour is re-
garded as a separate clinical entity (cHCC-CC — combined 
hepatocellular-cholangiocarcinoma). This type of cancer 
(cHCC-CC) was described for the first time in 1949 by Allen 
and Lis [1]. The cHCC-CC tumour is a rare malignant hepatic 
tumour and accounts for less than 1% of all primary mali-
gnant liver cancers [2]. This type of cancer is characterised by 
fast growth and a significant metastatic potential. It occurs 
more frequently in men than in women: 14:1 [3], usually in 
the seventh decade of life [2, 4]. The factors which might 
affect the development of this type of cancer comprise an 
infection with HCV, HBV and liver cirrhosis [3, 5, 7]. On the 
basis of clinical data and diagnostic imaging, a preoperative 
diagnosis is difficult [6]. The prognosis depends on the stage 
and is generally better than in CC but worse than in HCC. [2].
This paper presents the case report of a 62-year-old male 
patient undergoing a left hemihepatectomy for a cHCC-CC 
liver tumour.
The site’s observations
A 62-year-old male patient, without a history of on-
cological diseases was admitted to the Department of 
Surgical Oncology on account of a liver cancer diagnosed 
accidentally in an ultrasound examination. The abdominal 
ultrasound revealed a lesion with mixed echogenicity in 
the left (in accordance with surgical anatomy) liver lobe, 
measuring 77 × 60 mm. The lesion, involving segments: II, 
III, IVa and IVb was shown in the PET examination with SUV 
max (standard uptake value) measuring 9.8 (Fig. 1). Neither 
CT not Pet revealed any other disease foci, in particular — no 
involvement of the lymph nodes was found. The biochemi-
stry findings were the following: CA — 19.9–55.85 µ/ml, CEA 
— 8.46 ng/ ml, AFP — 20.94 ng/ml, ALAT — 860 µ/l. The re-
maining tests (including HBV and HCV) were unremarkable. 
The patient was qualified for surgery. During the in-
tervention, a tumour was found in the left hepatic lobe, 
involving the segments: II, III, IVa and IVb. A left hemihe-
patectomy with lymphangiectomy of the hepatoduodenal 
ligament and the splenic vein was performed The histo-
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pathological assessment revealed the architecture of two 
types of tumour: HCC and CC with a dominating histological 
component of HCC (Fig. 2) and two lymph nodes without 
cancer lesions. Both in the primary pathological report and 
in the microscopic assessment of the tumours performed 
later on (for the purposes of this publication), the differen-
tiation grade of the hepatocellular carcinoma (HCC) was 
defined as 3, whilst that of the bile duct cancer (CC) was 2. 
Additionally, in the case of both types of architecture, the 
signs of vascular involvement were found (LVI +).
The post-operative course was uneventful. The patient 
was discharged home on the 6th day post-op. Six mon-
ths after the surgery, a multifocal recurrence was found 
in the right hepatic lobe and verified with a transdermal 
Figure 1. The image of the tumour of the left liver love in PET imaging
Figure 2. In the bottom right corner the architecture of hepatocellular carcinoma is seen — the 
immunohistochemical reaction to the presence of Hep-Par-1 in the cancer cells is positive; in the top 
left corner the architecture of bile duct cancer is visible — the reaction to the presence of Hep-Par-1 is 
negative; magnification × 100
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core needle biopsy as CC. The patient was qualified for 
further surgery and chemotherapy with gemcitabine and 
cisplatin. The chemotherapy was discontinued on account 
of a myocardial infarction which had to be treated with an 
angioplasty. Eight months after the surgery, the patient lives 
with a symptomatic disease.
Discussion 
The presence of a tumour with an architecture invo-
lving both hepatocellular carcinoma and bile duct carci-
noma (cHCC-CC) in the liver is quite rare, accounting for 
< 1% of all primary liver cancers [2]. It is more prevalent 
in Caucasian males and among people above 65 years of 
age. The pathogenic factors affecting the development of 
this type of tumour have not been definitively established. 
The publications mention an infection with hepatotropic 
viruses (infections with HCV in 10–12% [5,8], with HBV in 
54% patients [5]) and liver cirrhosis occurring in 54% [5] as 
the predisposing factors for the development of cHCC-CC. 
On the basis of the analysis of the data from the SEER 
database (The Surveillance, Epidemiology, and End Results) 
covering 52 825 patients with primary liver cancers, inclu-
ding 465 patients with cHCC-CC, it was found that within this 
group of patients, a significantly worse prognosis concerns 
people of black race, with a significant progression of the 
disease and with the presence of tumours measuring from 5 
to 10 cm in diameter. Favourable prognostic factors affecting 
the improvement of prognoses in the multivariate analysis 
were diagnoses made after 1995 and extensive surgical 
intervention (tumour resection or liver transplant) [2]. In the 
analysis made by et al, adverse prognostic factors in cHCC-
-CC patients included: the presence of numerous tumours, 
lymph node involvement and the infiltration of the porta
vein or hepatic vein [8]. 
In comparison with other primary liver cancers, cHCC-
-CC can be characterised with medium prognosis. Overall
5-year survival in patients with this type of cancer is about 
10.5%, whilst in patients with CC it is 5.7%, and in patients
with HCC — 21% [2]. A radical resection of the tumour with 
cHCC-CC architecture allows for obtaining a 5-year survival 
rate reaching 28% [2], which is significantly worse than in
the case of a tumour resection in HCC tumour architecture, 
where the overall 5-year survival makes up 42.3% [9]. Overall
5-year survival after a liver transplant leads to 41.1% survival 
for cHCC-CC patients, whereas for CC tumours 3-year survival 
is obtained solely by 14.8% patients [10]. The results of the 
application of local ablation techniques in the treatment of 
cHCC-CC are poor [2].
Benefits in the use of chemotherapy in the treatment of 
cHCC-CC tumours have not been completely understood. 
The publications mention some isolated cases of the ap-
plication of chemotherapy (gemcitabine and cisplatin) in 
the dissemination stage of the cancer [11]. The use of other 
techniques, such as radiotherapy and transdermal ethanol 
injections, did not lead to any satisfactory results [12]. 
Within the post-operative follow-up, a periodic ultraso-
und and Ct evaluation is used as well as the measurement 
of the levels of AFP and CA19-9 in blood serum [12].
Patients with primary liver tumours of the cHCC-CC type, in 
comparison with other primary liver cancers, are characterised 
with moderate prognoses. The treatment of choice comprises 
extensive resection or — more rarely — a liver transplant. 
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